Abstract | BACKGROUND: METHODS: RESULTS: The primary outcome measure is cumulative number of remissions as a first event. Fifteen of 16 patients in group A and 14 of 16 patients in group B entered complete or partial remission as a first event. After a median follow-up of 24 months (interquartile range, 15 to 25 months), there were 4 complete remissions and 8 partial remissions in group A versus 8 complete remissions and 6 partial remissions in group B. Median proteinuria decreased from protein of 5.1 g/d (interquartile range, 4.0 to 7.3 g/d) to 2.1 g/d (interquartile range, 0.4 to 3.8 g/d; P = 0.004) in group A and 6.0 g/d (interquartile range, 4.4 to 8.5 g/d) to 0.3 g/d (interquartile range, 0.2 to 1.9 g/d; P = 0.049) in group B. Two patients from each group interrupted treatment because of side effects or inefficacy. CONCLUSION:
|
Authors | Claudio Ponticelli, Patrizia Passerini, Maurizio Salvadori, Carlo Manno, Battista Fabio Viola, Sonia Pasquali, Salvatore Mandolfo, Piergiorgio Messa |
Journal | American journal of kidney diseases : the official journal of the National Kidney Foundation
(Am J Kidney Dis)
Vol. 47
Issue 2
Pg. 233-40
(Feb 2006)
ISSN: 1523-6838 [Electronic] United States |
PMID | 16431252
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents, Alkylating
- Hormones
- Chlorambucil
- Cyclophosphamide
- Adrenocorticotropic Hormone
- Methylprednisolone
|
Topics |
- Adrenocorticotropic Hormone
(administration & dosage)
- Adult
- Aged
- Antineoplastic Agents, Alkylating
(administration & dosage)
- Chlorambucil
(administration & dosage)
- Cyclophosphamide
(administration & dosage)
- Drug Therapy, Combination
- Female
- Glomerulonephritis, Membranous
(drug therapy)
- Hormones
(administration & dosage)
- Humans
- Male
- Methylprednisolone
(administration & dosage)
- Middle Aged
- Nephrotic Syndrome
(drug therapy)
- Pilot Projects
- Prospective Studies
|